Just 1 in 10 back pain treatments work, study says — what to do instead
Only around one in every 10 treatments was found to be effective in relieving lower back pain, according to a new study published in BMJ Evidence-Based Medicine.
Many of them are "barely better than a placebo" in terms of pain relief, as stated in a press release from the University of New South Wales (UNSW) in Sydney, Australia.
'Dead Butt Syndrome' Could Happen After Sitting Too Long, Here's How To Avoid The Condition
"Our review did not find reliable evidence of large effects for any of the included treatments," said lead study author Dr. Aidan Cashin, deputy director of the Centre for Pain IMPACT at Neuroscience Research Australia (NeuRA) and conjoint senior lecturer in the School of Health Sciences at UNSW Sydney.
The researchers reviewed 301 randomized, controlled trials that included data on 56 non-surgical treatments for adults experiencing acute low back pain, chronic low back pain or a combination of both types, comparing them to groups that received placebos.
Read On The Fox News App
"Treatments included in the research were pharmacological, such as non-steroidal anti-inflammatory drugs – or NSAIDs – and muscle relaxants, but also non-pharmacological, like exercise and massage," Cashin said.
Ineffective treatments for acute low back pain included exercise, steroid injections and paracetamol (acetaminophen), the study found.
For chronic low back pain, antibiotics and anaesthetics were also "unlikely to be suitable treatment options," the study found.
For acute low back pain, non-steroidal anti-inflammatory drugs (NSAIDs) could be effective, the study found.
For chronic low back pain, therapies including exercise, taping, spinal manipulation, antidepressants and transient receptor potential vanilloid 1 (TRPV1) agonists may be effective — "however, those effects were small," Cashin noted.
The findings were "inconclusive" for many other treatments due to the "limited number of randomized participants and poor study quality," the researchers stated.
"We need further high-quality, placebo-controlled trials to understand the efficacy of treatments and remove the uncertainty for both patients and clinical teams," Cashin said.
Dr. Stephen Clark, a physical therapist and chief clinical officer at Confluent Health in Georgia, noted that the study was looking at "isolated interventions."
"They excluded studies where it was not possible to isolate the effectiveness of the target intervention," Clark, who was not involved in the study, told Fox News Digital.
Pain is a complex condition influenced by many different factors, according to Clark.
"Determining a specific cause of low back pain, particularly when the pain is persistent, is difficult, as the BMJ study points out," he said.
"Things like stress, sleep quality, fatigue, fear, social situations, nutrition, sickness and previous history of pain all play a role in how we experience pain."
Clark recommends "multimodal" treatments for pain, including multiple interventions tailored to each individual patient's experience.
Click Here To Sign Up For Our Health Newsletter
"Physical therapy research shows that manual therapy (joint mobilization/manipulation, soft tissue techniques), active interventions like exercise, and education about why you hurt and what to do about it is the ticket," he said.
"It's also important to remember that what worked for someone else might not be the exact pathway that works for you."
While surgical intervention can be effective for some patients, Clark noted that it can present its own challenges and should be a "last resort" for non-emergency situations.
For more Health articles, visit www.foxnews.com/health
"While surgery is indicated in some cases, it's almost never the answer in isolation," he said. "Understanding pain and the complexity around a person's situation must be in view."
"In many cases, conservative care can prevent or delay the need for invasive procedures."Original article source: Just 1 in 10 back pain treatments work, study says — what to do instead
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
12 hours ago
- The Hill
NYC identifies 3 new 9/11 victims who died at World Trade Center
Three new victims of the 9/11 attacks were identified this week by New York medical officials, nearly 24 years after the deadliest terrorist attack in American history. The New York City (NYC) Office of the Chief Medical Examiner identified Ryan Fitzgerald from New York, Barbara Keating from California and a third unnamed woman through DNA analysis. 'Each new identification testifies to the promise of science and sustained outreach to families despite the passage of time. We continue this work as our way of honoring the lost,' the chief medical examiner Dr. Jason K. Graham said in a Thursday statement. The examiners' office continues to reach out to family members for DNA reference samples' in its effort to identify victims. The Sept. 11, 2001, attack on the World Trade Center resulted in 2,753 deaths. According to the Medical Examiner's office, the three victims identified this week are the 1,651 st, 1,652 nd and 1,653 rd victims. About 1,100 victims of the deadly Al-Qaeda attacks remain unidentified. 'The pain of losing a loved one in the September 11th terror attacks echoes across the decades, but with these three new identifications, we take a step forward in comforting the family members still aching from that day,' Mayor Eric Adams said in a statement.
New York Post
13 hours ago
- New York Post
Trump can rein in healthcare costs AND win medical breakthroughs — here's how
Of all the problems bedeviling the American healthcare system, the high cost of pharmaceuticals is one of those most commonly cited by patients. Polling finds that most Americans think drugs are too expensive, and they're often right — even if pricey medications beat alternatives like surgery, hospitalization or living with pain. President Donald Trump has promised to implement healthcare reforms that both increase innovation and improve affordability. Advertisement Some see these as contradictory pursuits — but when it comes to pharmaceuticals, both of the president's goals can be achieved at the same time. This week the two of us, along with a team of top health and economic experts, launched Most Favored Patients, a working group aimed at developing reforms that will lower drug prices in ways that won't hinder or delay new drug development. Before we suggest policies that could work, let's be clear about what doesn't: government-mandated price controls. Advertisement Top-down edicts that remove the profit motive from drug research and development will do more harm than good, impeding the race to identify cures for cancer, Alzheimer's, Parkinson's, epilepsy and other cruel diseases. It's a short-sighted solution, too: It ignores the reality that 93% of US prescriptions are for very cheap generics — indeed, cheaper here than abroad — that emerge after innovators earn the necessary returns on their investments. Instead, let's try some innovations that make both medical and economic sense. First, do the easy stuff first and allow patients to buy medicines from pharmaceutical companies directly. Advertisement Our recent poll of 1,000 battleground-state voters found overwhelming 86% support for this concept, which would lower drug prices by avoiding expensive retail markups imposed by insurance companies and others. Most voters also favor Trump's intention to rein in costly middlemen like the highly concentrated pharmacy benefit manager industry, which negotiates drug prices for insurance companies. We also must require foreign countries to pay their fair share for medical innovations developed in the United States — that is, nearly all of them. Trump can use his NATO negotiations as a model here: Just as he has required Europe to pony up more for the benefits of NATO security through minimum levels of military spending, he could convince trading partners to spend more of their GDP on new drugs. Advertisement Right now, more than 70% of global pharmaceutical earnings come from the United States, even though we generate less than a quarter of global GDP. We annually spend $13,000 on healthcare per capita, while the rest of the developed world spends far less than $10,000 — partly because we allow more free-market healthcare pricing than other nations do. Trump is already implementing some of these reforms in his America First trade deals, securing some $300 billion worth of foreign commitments for new domestic pharmaceutical R&D, manufacturing and workforce investments. These commitments share the burden of finding cures that will benefit all of humanity — while fueling the American research engine that justifies the investments. Next, the Food and Drug Administration must thoroughly overhaul its antique, snail's-pace drug approval process: Many potential wonder drugs developed by small biomedical firms are shelved when that process' exorbitant costs and delays drain their capital. The FDA should fast-track experimental drugs for crippling and lethal diseases, and should expedite 'Right To Try' rules to get promising drugs to the people who need them. In addition, we believe the FDA should loosen its regulations and use economic criteria, not just clinical ones, to determine whether a drug may be fast-tracked for approval: Put simply, cheaper drugs should be allowed to come to market faster. Advertisement Finally, we're confident that price transparency in drugs and all other medical services would help drive prices down and encourage more comparison-shopping by patients. We don't buy food or gas or homes without knowing their price — but that's too often the case with drugs, hospitals and medical procedures. Republicans have been missing out on the political benefits of seizing on common-sense reforms like these. Advertisement Voters consistently view the GOP as being less caring and less reliable on solving our nation's healthcare concerns. That's made them cower. They keep their mouths shut and flee from any discussion of voters' valid complaints — and often lose elections as a result. As the midterms approach, Republicans who promote innovation with our Most Favored Patient proposals will help bring down costs, ensure American biomedical innovative supremacy, and save lives. Advertisement Everyone is on board with that. Stephen Moore is a co-founder of Unleash Prosperity, where Tomas Philipson is a senior research fellow.
Yahoo
14 hours ago
- Yahoo
60-Year-Old Gave Himself Early 20th Century Psychosis After He Went To ChatGPT For Diet Advice
A 60-year-old man gave himself an uncommon psychiatric disorder after asking ChatGPT for diet advice in a case published Tuesday by the American College of Physicians Journals. The man, who remained anonymous in the case study, told doctors he had eliminated sodium chloride, commonly known as table salt, from his diet after reading about its negative health effects. He said he could only find sources telling him how to reduce salt, but not eliminate it completely. Inspired by his nutrition studies in college, the man decided to completely eliminate sodium chloride from his diet as a personal experiment, with consultation from Chat GPT, researchers wrote. He maintained multiple dietary restrictions and even distilled his own water at home. 'For 3 months, he had replaced sodium chloride with sodium bromide obtained from the internet after consultation with ChatGPT, in which he had read that chloride can be swapped with bromide, though likely for other purposes, such as cleaning,' the case study read. While excess sodium can raise blood pressure and increase the risk of health issues, it is still necessary to consume a healthy amount of it. The man, who had no psychiatric history, eventually ended up at the hospital, worried that his neighbor was poisoning him. He told doctors he was very thirsty, but paranoid about the water he was offered. 'In the first 24 hours of admission, he expressed increasing paranoia and auditory and visual hallucinations, which, after attempting to escape, resulted in an involuntary psychiatric hold for grave disability,' the study read. Doctors concluded that the man was suffering from bromism, or bromide toxicity, a condition that is rare today but was more common in the early 20th century. The research noted that bromide was found in several over-the-counter medicines back then and contributed to up to 8% of bromism-related psychiatric admissions at that time. The hospital treated the man for psychosis and discharged him weeks later. His case highlights the potential pitfalls of using AI to seek medical tips. Dr. Margaret Lozovatsky, a pediatrician, warned last year that AI often misses crucial context. 'Even if the source is appropriate, when some of these tools are trying to combine everything into a summary, it's often missing context clues, meaning it might forget a negative,' she told the American Medical Association. 'So, it might forget the word 'not' and give you the opposite advice.' Related... ChatGPT Was Asked To List Everyone Trump Has Called 'A Low-IQ Individual' — And It's Pretty Racist Elon Musk Soft Launches 'NSFW' AI Companion A Week After Chatbot Goes On Antisemitic Tirade These Tragic AI Fails Are Proof That You Can't Fully Rely On ChatGPT To Plan Your Trip
